åêðáéäåõóçó γ.ν.α.

ΝΟΣΟΚΟΜΕΙΑΚΑ ΧΡΟΝΙΚΑ, ΤΟΜΟΣ 71, ΣΥΜΠΛΗΡΩΜΑ, 2009
535
3. Kolb H, Mittermuller J, Clemm C, et al. Donor leukocyte
transfusions for treatment of recurrent chronic
myelogenous leukemia in marrow transplant patients.
Blood 1990;76:2462-2465.
4. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versusleukemia
reactions after bone marrow transplantation.
Blood 1990;75:555-562.
5. Baron F, Sandmaier BM. Chimerism and outcomes after
allogeneic hematopoietic cell transplantation following
nonmyeloablative conditioning. Leukemia 2006;20:1690-
1700.
6. Peggs KS, Thomson K, Hart DP, et al. Dose-escalated
donor lymphocyte infusions following reduced intensity
transplantation: toxicity, chimerism, and disease
responses. Blood 2004;103:1548-1556.
7. Schetelig J, Thiede C, Bornhauser M, et al. Evidence of
a graft-versus-leukemia effect in chronic lymphocytic
leukemia after reduced-intensity conditioning and allogeneicstem-cell
transplantation: the Cooperative German
Transplant Study Group. J Clin Oncol 2003;21:2747-
2753.
8. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor
effects after allogeneic hematopoietic cell
transplantation with nonmyeloablative conditioning. J
Clin Oncol 2005;23:1993-2003.
9. Hegenbart U, Niederwieser D, Sandmaier BM, et al.
Treatment for acute myelogenous leukemia by lowdose,
total-body, irradiation-based conditioning and
hematopoietic cell transplantation from related and
unrelated donors. J Clin Oncol 2006;24:444-453.
10. Maris MB, Niederwieser D, Sandmaier BM, et al. HLAmatched
unrelated donor hematopoietic cell transplantation
after nonmyeloablative conditioning for patients with
hematologic malignancies. Blood 2003;102:2021-2030.
11.Barker JN, Weisdorf DJ, DeFor TE, et al. Rapid and
complete donor chimerism in adult recipients of unrelated
donor umbilical cord blood transplantation after
reduced-intensity conditioning. Blood 2003;102:1915-
1919.
12. Antin JH, Childs R, Filipovich AH, et al. Establishment of
complete and mixed donor chimerism after allogeneic
lymphohematopoietic transplantation: recommendations
from a workshop at the 2001 Tandem Meetings of the
International Bone Marrow Transplant Registry and the
American Society of Blood and Marrow Transplantation.
Biol Blood Marrow Transplant 2001;7:473-485.
13. Mielcarek M, Martin PJ, Leisenring W, et al. Graftversus-host
disease after nonmyeloablative versus
conventional hematopoietic stem cell transplantation.
Blood 2003;102:756-762.
14. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo
CAMPATH-1H prevents graft-versus-host disease following
nonmyeloablative stem cell transplantation.
Blood 2000;96:2419-2425.
15. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related
mortality following unrelated donor
stem cell transplantation by using a nonmyeloablative
conditioning regimen. Blood 2002;99:1071-1078.
16. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity
and mortality of HLA-matched unrelated donor
hematopoietic cell transplantation after nonmyeloablative
and myeloablative conditioning: influence of pretransplant
comorbidities. Blood 2004;104:961-968.
17. Diaconescu R, Flowers CR, Storer B, et al. Morbidity
and mortality with nonmyeloablative compared to
myeloablative conditioning before hematopoietic cell
transplantation from HLA matched related donors. Blood
2004;104:1550-1558.
18. Sorror ML, Maris MB, Storb R, et al. Hematopoietic
cell transplantation (HCT)-specific comorbidity index:
a new tool for risk assessment before allogeneic HCT.
Blood 2005;106:2912-2919.
19. Sorror ML, Maris MB, Sandmaier BM, et al. Hematopoietic
cell transplantation after nonmyeloablative
conditioning for advanced chronic lymphocytic leukemia.
J Clin Oncol 2005;23:3819-3829.
20. Thomson KJ, Morris EC, Milligan D, et al. Reduced
intensity allogeneic transplantation for non-Hodgkin’s
lymphoma: extended follow-up of an alemtuzumab-containing
regimen. Blood 2005;106:120a-121a. Abstract
401.
21. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic
hematopoietic cell transplantation after fludarabine and
2 Gy total body irradiation for relapsed and refractory
mantle cell lymphoma. Blood 2004;104:3535-3542.
22. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence
of a graft-versus-Hodgkin’s-lymphoma effect after
reduced-intensity allogeneic transplantation. Lancet
2005;365:1934-1941.
23. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative
outcome of reduced intensity and myeloablative
conditioning regimen in HLA identical sibling allogeneic
haematopoietic stem cell transplantation for patients
older than 50 years of age with acute myeloblastic
leukaemia: a retrospective survey from the Acute Leukemia
Working Party (ALWP) of the European group for
Blood and Marrow Transplantation (EBMT). Leukemia
2005;19:2304-2312.
24. Crawley C, Szydlo R, Lalancette M, et al. Outcomes of
reduced-intensity transplantation for chronic myeloid
leukemia: an analysis of prognostic factors from the
Chronic Leukemia Working Party of the EBMT. Blood
2005;106:2969-2976.
25. Scott BL, Sandmaier BM. Reduced-intensity allogeneic
bone marrow transplantation: Outcomes with myeloid
malignancies. Hematology Am Soc Hematology Educ
Program 2006:381-389.
26. Badros A, Barlogie B, Morris C, et al. High response
rate in refractory and poor-risk multiple myeloma after
allotransplantation using a nonmyeloablative condition-